Advertisement
Advertisement
TARS
Tarsus Pharmaceuticals, Inc. Common Stock
64.70
USDSponsored
+2.71
+4.37%
Feb 06, 15:59 UTC -5
Closed
After-Market
64.70
0.00
+0.01%
TARS Earnings Reports
Positive Surprise Ratio
TARS beat 15 of 21 last estimates.
71%
Next Report
Date of Next Report
Feb 23, 2026
Estimate for Q4 25 (Revenue/ EPS)
$147.53M
/-$0.09
Implied change from Q3 25 (Revenue/ EPS)
+24.29%
/-70.00%
Implied change from Q4 24 (Revenue/ EPS)
+122.16%
/-85.00%
Tarsus Pharmaceuticals, Inc. Common Stock earnings per share and revenue
On Nov 04, 2025, TARS reported earnings of -0.30 USD per share (EPS) for Q3 25, beating the estimate of -0.35 USD, resulting in a 16.06% surprise. Revenue reached 118.70 million, compared to an expected 117.53 million, with a 1.00% difference. The market reacted with a -4.62% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 11 analysts forecast an EPS of -0.09 USD, with revenue projected to reach 147.53 million USD, implying an decrease of -70.00% EPS, and increase of 24.29% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
Adaptive Biotechnologies Corporation Common Stock
Report Date
Feb 05, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.09
Surprise
+51.33%
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
FAQ
What were Tarsus Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Tarsus Pharmaceuticals, Inc. Common Stock reported EPS of -$0.30, beating estimates by 16.06%, and revenue of $118.70M, 1% above expectations.
How did the market react to Tarsus Pharmaceuticals, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -4.62%, changed from $71.50 before the earnings release to $68.20 the day after.
When is Tarsus Pharmaceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for Feb 23, 2026.
What are the forecasts for Tarsus Pharmaceuticals, Inc. Common Stock's next earnings report?
Based on 11
analysts, Tarsus Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.09 and revenue of $147.53M for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement